NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

The Defense rests.


"This Phase III trial reached data lock and top line data was recently presented."

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed and recurrent Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” This Phase III trial reached data lock and top line data was recently presented. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.




https://nwbio.com/northwest-biotherapeutics-announces-presentations-on-dcvax-l-personalized-vaccines-manufacturing-and-scale-up-and-dcvax-l-clinical-program/
Margin Buu

Wednesday, June 08, 2022 8:56:44 AM

Re: biosectinvestor post# 484397

Post#
484456
of 484508
EXCELLENT SUMMARY & DISTINCTIONS

I'd like to highlight an excerpt from your post but it's all valuable and should be read by all investors who are interested in learning that "The company has not released a statement ON TLD. Period. They have not done so because they are are embargoed as well, but there has ALWAYS been an exception for scientific presentations."


biosectinvestor

Member Level
Wednesday, June 08, 2022 2:33:49 AM

Re: PhyInvestor1 post# 484371

Post#
484397
of 484504
The TLD is NOT on the company website. The slides are not on the company website and neither is the Video. This is a giant departure from any other past presentation that the company RELEASED.

The third-party has put it out. It was presented in a scientific meeting, yes, but NOT by the company. No employee of the company is a presenter. Nowhere has the company provided a summary of endpoints directly in their own release. Even the link, is to a third-party website, a charity, linking just to the slides and full video, no summary.

So you are correct that therefore NO MEDIA really can cover it, except that Adam Feuerstein did. He is not subject to the embargo. Why is that? Because he is not going through the company or seeking access to them apparently, other than as a gotcha journalist.

To say they have not "advertised release" is a misnomer. The company has not released a statement ON TLD. Period. They have not done so beause they are are embargoed as well, but there has ALWAYS been an exception for scientific presentations. No one is saying there isn't. I'm not saying that third-parties were unable to present the data, nor that they did not present the data. Obviously they did.

But that is not an official release in the sense that it can't generate any real coverage, and therefore the market has not yet taken notice of anything EXCEPT Adam Feuerstein's false article because that is the only reporting so far, and it is effectively unofficial reporting because he is not seeking to be a part of the official release by the company or the journal. He was, I understand, officially barred from the NYAS event.

Trying to convince people that this scientific presentation WAS THE RELEASE is a way of convincing people that nothing further will come of this, and I believe you're misleading yourself and others if you think that is the case.

Reporting and coverage come when the journal is released or, absent that, the company actually does a press release stating the end points and general highlights of the trial in an official and complete statement. THAT has not happened yet.

You can keep two different thoughts in your head at once? Scientific presentation is OK, because it's not an official release or publication or press. It is merely a scientific presentation, very narrow cast. That is why it is an exception to the embargo. If it were intended to get worldwide press coverage, that would violate the purpose of the embargo and then not be an exception to the embargo policy.

You have to understand the purpose of the embargo. The journal wants to be the first to publish the results definitively, and to present NOVEL results. If they had sought worldwide coverage of NYAS and published the results on their website, that would be giving media the OK to publish as well. That clearly has not yet been given, because they are seeking publication first.

And if you go back to the interim results, all the coverage basically references the JOURNAL article. They had worldwide reports on interim results, which was great, but it did not come until there was an official release of data in the journal. That is yet to come in the case of TLD, and when that happens, it seems quite obvious and likely that worldwide coverage will begin, most likely starting in the UK press, but it would be nice if the home press started. We'll see.
Seamlessly connect w/ the markets on the E*TRADE Mobile app